Anti-inflammatory effect of aprotinin: A meta-analysis

Journal of Extra-Corporeal Technology

Volumn 41, Issue 2, 2009, Pages 79-86

  Brown, Jeremiah R ^a   Toler, Andrew W J ^a   Kramer, Robert S ^b   Clive Landis, R ^c  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^b MAINE MEDICAL CENTER   (United States)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Aprotinin; Inflammation; Meta analysis; Surgery

Indexed keywords

APROTININ; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; ACUTE PHASE PROTEIN; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE;

ANTIINFLAMMATORY ACTIVITY; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONFERENCE PAPER; HEART SURGERY; HUMAN; LOW DRUG DOSE; META ANALYSIS; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; SURGICAL PATIENT; SYSTEMATIC REVIEW; ADULT; ARTICLE; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ACUTE-PHASE PROTEINS; ADULT; ANTI-INFLAMMATORY AGENTS; APROTININ; CARDIAC SURGICAL PROCEDURES; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349570403     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993;55:552-9.
2. Landis C. Why the inflammatory response is important to the cardiac surgical patient. J Extra Corpor Technol. 2007;39:281-4.
3. Landis C. Pharmacologic strategies for combating the inflammatory response. J Extra Corpor Technol. 2007;39:291-5.
4. Greilich PE, Brouse CF, Rinder CS, et al. Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology. 2004;100:225-33.
5. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442-8.
6. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Data Syst Rev 2001;1:CD001886.
7. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-31.
8. Mangano DT, Tudor IC, Dietzel C. Multicenter study of perioperative ischemia research G, ischemia R, education F. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-65.
9. Westaby S. Aprotinin: twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg. 2008;135:487-91.
10. Asimakopoulos G, Lidington EA, Mason J, Haskard DO, Taylor KM, Landis RC. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg. 2001;122:123-8.
11. Asimakopoulos G, Taylor KM, Haskard DO, Landis RC. Inhibition of neutrophil L-selectin shedding: A potential anti-inflammatory effect of aprotinin. Perfusion. 2000;15:495-9.
12. Day JR, Haskard DO, Taylor KM, Landis RC. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation. Ann Thorac Surg. 2006;81:619-24.
13. Day JR, Landis RC, Taylor KM. Aprotinin and the protease-activated receptor 1 thrombin receptor: Antithrombosis, inflam mation, and stroke reduction. Semin Cardiothorac Vasc Anesth. 2006; 10:132-42.
14. Day JR, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2006; 131:21-7.
15. Pruefer D, Makowski J, Dahm M, et al. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg. 2003;75:210-5.
16. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-9.
17. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: A randomized, double-blind, placebocontrolled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg. 2003;126:1498-503.
18. Harig F, Feyrer R, Mahmoud FO, Blum U, von der Emde J. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac Cardiovasc Surg. 1999;47:111-8.
19. Schmartz D, Tabardel Y, Preiser JC, et al. Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients? J Thorac Cardiovasc Surg. 2003;125:184-90.
20. Isbir CS, Dogan R, Demircin M, Yaylim I, Pasaoglu I. Aprotinin reduces the IL-8 after coronary artery bypass grafting. Cardiovasc Surg. 2001;9:403-6.
21. Koster A, Huebler S, Merkle F, et al. Heparin-level-based anticoagulation management during cardiopulmonary bypass: A pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesth Analg. 2004;98:285-90.
22. Lei Y, Haider H, Chusnsheng W, et al. Dose-dependent effect of aprotinin on aggravated pro-inflammatory cytokines in patients with pulmonary hypertension following cardiopulmonary bypass. Cardiovasc Drugs Ther. 2003;17:343-8.
23. Wei M, Kuukasjarv P, Laurikka J, et al. Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. Cardiovasc Drugs Ther. 2002;16:37-42.
24. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 2000;69:1084-91.
25. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;110:1658-62.
26. Turkoz A, Cigli A, But K, et al. The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery. J Cardiothorac Vasc Anesth. 2001;15:603-10.
27. Diego RP, Mihalakakos PJ, Hexum TD, Hill GE. Methylprednisolone and full-dose aprotinin reduce reperfusion injury after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997;11:29-31.
28. Goudeau JJ, Clermont G, Guillery O, et al. In high-risk patients, combination of antiinflammatory procedures during cardiopulmonary bypass can reduce incidences of inflammation and oxidative stress. J Cardiovasc Pharmacol. 2007;49:39-45.
29. Kaminishi Y, Hiramatsu Y, Watanabe Y, Yoshimura Y, Sakakibara Y. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Ann Thorac Surg. 2004;77:644-50.
30. Tassani P, Augustin N, Barankay A, Braun SL, Zaccaria F, Richter JA. High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2000;14:682-6.
31. Wei M, Kuukasjarvi P, Laurikka J, et al. Pump prime aprotinin fails to limit proinflammatory cytokine release after coronary artery bypass surgery. Scand Cardiovasc J. 2001;35:50-4.
32. Greilich PE, Okada K, Latham P, Kumar RR, Jessen ME. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: Randomized, doubleblind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. Circulation. 2001;104(Suppl 1):I265-9.
33. Hill GE, Diego RP, Stammers AH, Huffman SM, Pohorecki R. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg. 1998;65:66-9.
34. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896-900.
35. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials. 1996;17:1-12.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
37. Baufreton C, Jansen PG, Le Besnerais P, et al. Heparin coating with aprotinin reduces blood activation during coronary artery operations. Ann Thorac Surg. 1997;63:50-6.
38. Cicekcioglu F, Cagli K, Emir M, et al. Effects of minimal dose aprotinin on blood loss and fibrinolytic system-complement acti vation in coronary artery bypass grafting surgery. J Card Surg. 2006;21:336-41.
39. Gott JP, Cooper WA, Schmidt FE Jr, et al. Modifying risk for extracorporeal circulation: Trial of four antiinflammatory strategies. Ann Thorac Surg. 1998;66:747-53.
40. Casati V, Della Valle P, Benussi S, et al. Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques. J Thorac Cardiovasc Surg. 2004;128:83-91.
41. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33:479-94.
42. Royston D, Cardigan R, Gippner-Steppert C, Jochum M. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? Anesth Analg. 2001;92:830-6.
43. Landis RC, Arrowsmith JE, Baker RA, et al. Consensus statement: Defining the minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum. 2008;11:290-6.
44. Royston D, Kovesi T, Marczin N. The unwanted response to cardiac surgery: Time for a reappraisal? J Thorac Cardiovasc Surg. 2003; 125:32-5.
45. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2000;69:1192-7.
46. Evans BJ, Haskard DO, Finch JR, Hambleton IR, Landis RC, Taylor KM. The inflammatory effect of cardiopulmonary bypass on leukocyte extravasation in vivo. J Thorac Cardiovasc Surg. 2008;135:999-1006.
47. Tahamont MV, Barie PS, Blumenstock FA, Hussain MH, Malik AB. Increased lung vascular permeability after pancreatitis and trypsin infusion. Am J Pathol. 1982;109:15-26.